ARCT

14.34

6.62% 0.89

Handel nachbörslich: 14.02 -0.32 -2.23%

Arcturus Therapeutics Holdings Inc (ARCT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$13.45

Offen:

$13.325

24-Stunden-Volumen:

2.41M

Relative Volume:

3.80

Marktkapitalisierung:

$407.59M

Einnahmen:

$42.35M

Nettoeinkommen (Verlust:

$-78.67M

KGV:

-5.0921

EPS:

-2.8161

Netto-Cashflow:

$-63.18M

1W Leistung:

+76.17%

1M Leistung:

+159.31%

6M Leistung:

+75.31%

1J Leistung:

-22.53%

1-Tages-Spanne:

$12.42

$14.53

1-Wochen-Bereich:

$8.03

$14.53

52-Wochen-Spanne:

$5.50

$24.17

Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile

Firmenname

Arcturus Therapeutics Holdings Inc

Sektor

Healthcare (1033)

Branche

Biotechnology (582)

Telefon

(858) 900-2660

Adresse

10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA

Mitarbeiter

111

Twitter

@ArcturusRx

Nächster Verdiensttermin

2026-08-10

Neueste SEC-Einreichungen

ARCT's Discussions on Twitter

Compare ARCT vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ARCT Arcturus Therapeutics Holdings Inc	14.34	312.37M	42.35M	-78.67M	-63.18M	-2.8161
VRTX Vertex Pharmaceuticals Inc	547.59	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	828.50	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,011.11	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.89	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	211.58	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-18	Eingeleitet	B. Riley Securities	Buy
2026-01-23	Eingeleitet	Roth Capital	Buy
2025-10-24	Herabstufung	H.C. Wainwright	Buy → Neutral
2025-10-23	Herabstufung	Citigroup	Buy → Neutral
2025-10-22	Herabstufung	Guggenheim	Buy → Neutral
2025-09-04	Fortgesetzt	H.C. Wainwright	Buy
2025-05-28	Eingeleitet	Scotiabank	Sector Outperform
2025-01-28	Eingeleitet	BTIG Research	Buy
2024-08-12	Eingeleitet	Leerink Partners	Outperform
2023-12-13	Eingeleitet	Canaccord Genuity	Buy
2023-07-24	Eingeleitet	William Blair	Outperform
2023-05-11	Hochstufung	H.C. Wainwright	Neutral → Buy
2022-11-14	Fortgesetzt	Wells Fargo	Overweight
2022-11-10	Herabstufung	Robert W. Baird	Neutral → Underperform
2022-11-03	Hochstufung	Citigroup	Neutral → Buy
2022-11-02	Hochstufung	Barclays	Underweight → Equal Weight
2022-08-10	Herabstufung	Raymond James	Mkt Perform → Underperform
2022-07-19	Fortgesetzt	Cantor Fitzgerald	Overweight
2022-05-11	Hochstufung	Robert W. Baird	Underperform → Neutral
2022-04-21	Herabstufung	Citigroup	Buy → Neutral
2022-01-31	Hochstufung	Raymond James	Underperform → Mkt Perform
2021-08-12	Herabstufung	Raymond James	Mkt Perform → Underperform
2021-08-11	Herabstufung	Goldman	Neutral → Sell
2021-08-10	Herabstufung	Robert W. Baird	Neutral → Underperform
2021-07-02	Eingeleitet	Cantor Fitzgerald	Overweight
2021-06-25	Fortgesetzt	Goldman	Neutral
2021-06-21	Herabstufung	Barclays	Equal Weight → Underweight
2021-06-04	Fortgesetzt	Robert W. Baird	Neutral
2021-02-17	Herabstufung	B. Riley Securities	Neutral → Sell
2021-01-19	Herabstufung	B. Riley Securities	Buy → Neutral
2021-01-15	Herabstufung	B. Riley Securities	Buy → Neutral
2021-01-07	Eingeleitet	Wells Fargo	Overweight
2020-12-29	Herabstufung	Barclays	Overweight → Equal Weight
2020-12-29	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-12-29	Herabstufung	Raymond James	Outperform → Mkt Perform
2020-12-29	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-12-23	Herabstufung	ROTH Capital	Buy → Sell
2020-12-08	Bestätigt	B. Riley Securities	Buy
2020-12-07	Bestätigt	B. Riley Securities	Buy
2020-10-26	Eingeleitet	Barclays	Overweight
2020-10-06	Eingeleitet	Citigroup	Buy
2020-08-26	Eingeleitet	Piper Sandler	Overweight
2020-07-30	Fortgesetzt	ROTH Capital	Buy
2020-07-16	Eingeleitet	Raymond James	Outperform
2020-07-13	Eingeleitet	B. Riley FBR	Buy
2020-06-09	Herabstufung	WBB Securities	Buy → Hold
2020-02-11	Eingeleitet	Robert W. Baird	Outperform
2020-02-07	Eingeleitet	Guggenheim	Buy
2020-02-06	Eingeleitet	Guggenheim	Buy
2019-04-05	Eingeleitet	H.C. Wainwright	Buy
2018-09-20	Hochstufung	WBB Securities	Buy → Strong Buy
2018-01-22	Eingeleitet	Chardan Capital Markets	Buy

Alle ansehen

Arcturus Therapeutics Holdings Inc Aktie (ARCT) Neueste Nachrichten

Aug 21, 2026

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Aug 21, 2026

Aug 19, 2026

Arcturus (ARCT) Results Review: EPS Comes in Above Forecast in the Latest Reading; Stock Move: The Market Price Advances 19.85% on the DayGeographic Revenue Trends - Vinanet

Aug 19, 2026

Elon Musk Says mRNA Has 'Tremendous Promise,' Turning Disease Into a 'Software Problem,' as Moderna Stock Rockets 177% on Cancer Vaccine Breakthrough - Sahm

Aug 19, 2026

Aug 17, 2026

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Aug 17, 2026

Aug 16, 2026

Liquidity Mapping Around (ARCT) Price Events - Stock Traders Daily

Aug 16, 2026

Aug 14, 2026

We're Keeping An Eye On Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate - Moomoo

Aug 14, 2026

Dimensional Fund Advisors LP Decreases Holdings in Arcturus Therapeutics Holdings Inc. $ARCT - MarketBeat

Aug 14, 2026

Aug 13, 2026

Arcturus Therapeutics (ARCT) Surges 5.92% to $8.05, Approaches Key Resistance at $8.45Low Volatility Picks - vinanet.vn

Aug 13, 2026

HC Wainwright Has Optimistic Outlook of ARCT Q3 Earnings - MarketBeat

Aug 13, 2026

Aug 11, 2026

Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline - MarketBeat

Aug 11, 2026

H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Hold Rating, Maintains Target Price $9 - Moomoo

Aug 11, 2026

Aug 10, 2026

BTIG Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $23 - Moomoo

Aug 10, 2026

Aug 09, 2026

Arcturus Therapeutics (NASDAQ:ARCT) Rating Increased to Sell at Wall Street Zen - MarketBeat

Aug 09, 2026

Aug 07, 2026

Arcturus Therapeutics (NASDAQ:ARCT) Announces Earnings Results, Beats Estimates By $0.16 EPS - MarketBeat

Aug 07, 2026

A Quick Look at Today's Ratings for Arcturus Therapeutics(ARCT.US), With a Forecast Between $20 to $20 - Moomoo

Aug 07, 2026

Arcturus Therapeutics Holdings Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 232% Upside - TradingView

Aug 07, 2026

CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Cuts Target Price to $20 - Moomoo

Aug 07, 2026

Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress - BioSpace

Aug 07, 2026

ARCT Looks 57.9% Overvalued on GF Value™ - GuruFocus

Aug 07, 2026

Aug 06, 2026

Earnings call transcript: Arcturus Therapeutics tops Q2 2026 EPS view By Investing.com - Investing.com South Africa

Aug 06, 2026

Arcturus Therapeutics Q2 Earnings Call Highlights - MarketBeat

Aug 06, 2026

Earnings call transcript: Arcturus Therapeutics tops Q2 2026 EPS view - Investing.com

Aug 06, 2026

Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Aug 06, 2026

Arcturus Therapeutics Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 06, 2026

Arcturus Therapeutics Holdings Inc. Q2 2026: Revenue $2.96M, EPS $(0.84) — 10-Q Summary - TradingView

Aug 06, 2026

Q2 2026 Arcturus Therapeutics Holdings Inc Earnings Call Transcript - GuruFocus

Aug 06, 2026

Arcturus Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo

Aug 06, 2026

Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 06, 2026

Arcturus Therapeutics reports Q2 2026: $3.0M revenue, $23.8M net loss, $191.5M cash - TradingView

Aug 06, 2026

Arcturus Therapeutics: Q2 Earnings Snapshot - marketscreener.com

Aug 06, 2026

Aug 05, 2026

Why (ARCT) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Aug 05, 2026

Earnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Q2 2026 -- GF Value Sees 44% Downside - Yahoo Finance

Aug 05, 2026

Aug 04, 2026

Arcturus Therapeutics Holdings Inc expected to post a loss of 100 cents a shareEarnings Preview - TradingView

Aug 04, 2026

Aug 02, 2026

ARCT Q1 2026 Earnings: Loss Narrower Than Expected as Shares Dip 2.7%Earnings Quality Score - Vinanet

Aug 02, 2026

Aug 01, 2026

Arcturus Therapeutics (NASDAQ:ARCT) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat

Aug 01, 2026

Jul 31, 2026

Arcturus Therapeutics (ARCT) to Announce Quarterly Earnings on Thursday - MarketBeat

Jul 31, 2026

Jul 29, 2026

Arcturus Therapeutics (ARCT) Slips 0.61% as Stock Hovers Near Key Support LevelMomentum ETF - vinanet.vn

Jul 29, 2026

Jul 28, 2026

Arcturus Therapeutics Q2 Results: Financials and update due Aug 6 - scanx.trade

Jul 28, 2026

Jul 27, 2026

Arcturus Therapeutics Holdings Inc - TradingKey

Jul 27, 2026

Jul 26, 2026